- PA5-95505 - Invitrogen Antibodies S100A10 antibody

Submitted references Multiple therapeutic effects of human neural stem cells derived from induced pluripotent stem cells in a rat model of post-traumatic syringomyelia.

Xu T, Li X, Guo Y, Uhlin E, Holmberg L, Mitra S, Winn D, Falk A, Sundström E
EBioMedicine 2022 Mar;77:103882

Photobiomodulation Promotes Repair Following Spinal Cord Injury by Regulating the Transformation of A1/A2 Reactive Astrocytes.

Wang X, Zhang Z, Zhu Z, Liang Z, Zuo X, Ju C, Song Z, Li X, Hu X, Wang Z
Frontiers in neuroscience 2021;15:768262

Melatonin Ameliorates Axonal Hypomyelination of Periventricular White Matter by Transforming A1 to A2 Astrocyte via JAK2/STAT3 Pathway in Septic Neonatal Rats.

Jiang S, Wang H, Zhou Q, Li Q, Liu N, Li Z, Chen C, Deng Y
Journal of inflammation research 2021;14:5919-5937

Sequential progenitor states mark the generation of pancreatic endocrine lineages in mice and humans.

Yu XX, Qiu WL, Yang L, Wang YC, He MY, Wang D, Zhang Y, Li LC, Zhang J, Wang Y, Xu CR
Cell research 2021 Aug;31(8):886-903

AIM2 inflammasome mediates hallmark neuropathological alterations and cognitive impairment in a mouse model of vascular dementia.

Poh L, Fann DY, Wong P, Lim HM, Foo SL, Kang SW, Rajeev V, Selvaraji S, Iyer VR, Parathy N, Khan MB, Hess DC, Jo DG, Drummond GR, Sobey CG, Lai MKP, Chen CL, Lim LHK, Arumugam TV
Molecular psychiatry 2021 Aug;26(8):4544-4560

Contribution of endogenous antibodies to learning deficits and astrocytosis in human P301S mutant tau transgenic mice.

van der Hoven J, van Hummel A, Przybyla M, Asih PR, Gajwani M, Feiten AF, Ke YD, Ittner A, van Eersel J, Ittner LM
Scientific reports 2020 Aug 14;10(1):13845

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence analysis of S100A10 in A549 cell. Antigen retrieval was performed on the tissue using IHC enzyme antigen retrieval reagent and blocked with 10% goat serum. Samples were incubated with S100A10 polyclonal antibody (Product # PA5-95505) at a 2 µg/mL dilution, followed by 488 conjugated goat anti-rabbit IgG using a 1:100 dilution and DAPI.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence analysis of S100A10 in A549 cell. Antigen retrieval was performed on the tissue using IHC enzyme antigen retrieval reagent and blocked with 10% goat serum. Samples were incubated with S100A10 polyclonal antibody (Product # PA5-95505) at a 2 µg/mL dilution, followed by 488 conjugated goat anti-rabbit IgG using a 1:100 dilution and DAPI.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence analysis of S100A10 in A431 cell. Antigen retrieval was performed on the tissue using IHC enzyme antigen retrieval reagent and blocked with 10% goat serum. Samples were incubated with S100A10 polyclonal antibody (Product # PA5-95505) at a 2 µg/1x10^6 cells dilution, followed by 488 conjugated goat anti-rabbit IgG using a 1:100 dilution and DAPI.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence analysis of S100A10 in A549 cell. Antigen retrieval was performed on the tissue using IHC enzyme antigen retrieval reagent and blocked with 10% goat serum. Samples were incubated with S100A10 polyclonal antibody (Product # PA5-95505) at a 2 µg/mL dilution, followed by 488 conjugated goat anti-rabbit IgG using a 1:100 dilution and DAPI.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Flow cytometry of S100A10 in A549 cells (blue line), isotype control rabbit IgG (green line) and unlabeled (red line). Samples were blocked with 10% goat serum, incubated with S100A10 polyclonal antibody (Product # PA5-95505) at a dilution of 1 µg (per 1x10^6 cells), followed by 488 conjugated goat anti-rabbit IgG (30 min at 20°C) using a 5-10 µg (per 1x10^6 cells) dilution.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Flow Cytometry of S100A10 in A431 cells (blue line), isotype control rabbit IgG (green line) and unlabeled (red line). Samples were blocked with 10% goat serum, incubated with S100A10 Polyclonal Antibody (Product # PA5-95505) at a dilution of 1 μg (per 1x10^6 cells), followed by DyLight®488 conjugated goat anti-rabbit IgG (for 30 minutes at 20°C) using 5-10 μg (per 1x10^6 cells) dilution.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 3 Photobiomodulation modulated the transformation of A1/A2 astrocytes. (A) Representative images of immunofluorescence staining for GFAP (green) and C3 (red) or S100a10 (red) in the lesion area 150 mum from the epicenter in the SCI + vehicle and SCI + PBM groups at 7 and 14 dpi. Scale bar: 200 mum. (B) Western blot analysis and quantification of the expression levels of C3 and S100a10 in each group at 7 dpi ( n = 3 individuals per group). (C) Representative immunofluorescence images of GFAP (green) and C3 (red) or S100a10 (red) in astrocytes in the control, control + PBM, A1, and A1 + PBM groups. Con, control; A1, A1 astrocytes. Scale bar: 200 mm. (D) Representative blots and quantification of the expression levels of C3 and S100a10 in each group. The experiments were independently repeated three times. * p < 0.05, ** p < 0.01, *** p < 0.001.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 4 Signaling pathways involved in A1/A2 astrocyte activation were regulated by PBM. (A) GO function analysis between the SCI-7d group and sham control group. The inflammatory response and immune system process were dramatically activated. (B) The histogram shows the -log10 ( p -value) of the NF-kappaB pathway, PI3K-Akt pathway, JAK-STAT pathway, and Notch pathway (comparison between multiple groups vs. the sham control group), as determined by KEGG enrichment analysis. (C) Western blot analysis of the expression of proteins related to the NF-kappaB signaling pathway, JAK2-STAT3 signaling pathway, and PI3K-Akt signaling pathway in the sham control, SCI + vehicle, and SCI + PBM groups at 7 dpi. Quantification of the relative protein levels of pNF-kappaB, NF-kappaB, pJAK2, JAK2, pSTAT3, STAT3, pPI3K, PI3K, pAkt, and Akt. n = 3 individuals per group. ** p < 0.01, *** p < 0.001, the SCI + vehicle group vs. the sham control group; ## p < 0.01, the SCI + PBM group vs. the SCI + vehicle group. (D) Representative blots and quantification of the relative levels of pNF-kappaB, NF-kappaB, Notch1, pJAK2, JAK2, pSTAT3, STAT3, pPI3K, PI3K, pAkt, and Akt in the control, control + PBM, A1, and A1 + PBM groups. Con, control; A1, A1 astrocytes. The experiments were independently repeated three times. ** p < 0.01, *** p < 0.001, **** p < 0.0001, the A1 group vs. the control group; ## p < 0.01, ### p < 0.001, the A1 + PBM group vs. the A1 group. (E) Representative blots and quantification o

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 Melatonin reversed the increased expression of C3, and decreased expression of S100A10 in primary astrocytes stimulated by IL-1alpha, TNF-alpha and C1q in vitro. After melatonin treatment and IL-1alpha, TNF-alpha and C1q exposure, the astrocytes were processed for immunofluorescence staining using primary antibodies GFAP (green), and anti-C3 (red) for A1 detection. Immunofluorescence images of cultured primary astrocytes showing the expression of GFAP and C3 at 24h after the treatment with IL-1alpha + C1q + TNF-alpha, IL-1alpha + C1q + TNF-alpha + melatonin and IL-1alpha + C1q + TNF-alpha + melatonin + luzindole when compared with the corresponding control ( A ). ( B ) Shows the optical density changes of C3 protein relative to GAPDH. A2 astrocytes were examined by immunofluorescence labeling using anti-GFAP (green) and A2 marker anti-S100A10 (red). Immunofluorescence images of cultured primary astrocytes showing expression of GFAP and S100A10 at 24h after treatment of IL-1alpha + C1q + TNF-alpha, IL-1alpha + C1q + TNF-alpha + melatonin, and IL-1alpha + C1q + TNF-alpha + luzindole when compared with the corresponding control ( C ). ( D ) Shows the optical density changes of S100A10 protein, relative to GAPDH. Scale bars: 20 mum. * P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Reactive astrocytes and scar-forming astrocytes were affected by transplanted NESCs. (a) Spinal cord sections of lesion sites from vehicle treated rats in chronic transplantation condition showing a large cyst surrounded by parenchyma stained for GFAP (green) and S100A10 (red). (b) Spinal cord sections of lesion site from vehicle and NESCs groups after chronic transplantation stained for HuNu (green), CSPG4 (red) and DAPI (blue). (c) Spinal cord sections of lesion sites stained for HuNu (green) and GFAP (red) from both vehicle and NESCs groups 10 weeks after subacute or chronic transplantation. (d) Quantification of the GFAP positive area to whole section of the experiment illustrated in b (mean +- SEM, two-tailed t-test, subacute: p < 0*01, n = 5 and 6 rats, respectively, chronic: no statistical significance, n = 6). (e) Spinal cord sections of lesion sites from vehicle and NESCs groups 10 weeks after subacute or chronic transplantation stained for ED1. (f) Magnified image of the boxed area in e. (g) Quantification of ED1 positive cells 10 weeks after subacute or chronic transplantation as described in E (mean +- SEM, two-tailed t-test, subacute: p < 0*05, n = 5 and 9 rats, respectively, chronic: p < 0*05, n = 7 rats per group). Section thickness = 10 um. Figure5

PA5-95505

Antibody data